Clinical Trial Update: Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a combination of temozolomide, bevacizumab, and bortezomib in recurrent glioblastoma multiforme has completed enrollment and phase 1 as…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• Bevacizumab (bevacizumab)
• Bortezomib (bortezomib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Emory University | Conditions: Glioblastoma Multiforme | Phase 1 | Status: COMPLETED